Scinai Immunotherapeutics (SCNI) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SCNI Scinai Immunotherapeutics

Watchlist

3.500
+0.170+5.11%

Close Sep 10 16:00 ET

3.689
+0.189+5.39%

Post 19:13 ET

2.93MMarket Cap0.00P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.
GlobeNewswireSep 9 11:12 ET
Scinai Immunotherapeutics Shares Are Trading Higher After the Company Announced It Regained Compliance With the Nasdaq.
BenzingaAug 29 08:43 ET
Scinai Regains Full Compliance With Nasdaq Listing Requirements
newsfilter.ioAug 29 06:31 ET
Scinai Immunotherapeutics Restructures Debt, Boosts Equity
TipRanksAug 21 09:27 ET
Press Release: Scinai Announces Closing of Loan Restructuring Agreement With European Investment Bank Converting Approximately $29 Million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
Dow JonesAug 21 08:45 ET
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript Summary
moomoo AIAug 20 15:05 ET · Conference Call

Comments

Trytosaveabit

Aug 29 05:40

Update

$Scinai Immunotherapeutics (SCNI.US)$ Scinai Regains Full Compliance with Nasdaq Listing Requirements
9 MINUTES AGO, 6:31 AM EDT
VIA PR NEWSWIRE

Stock Region

Jul 15 17:34

Biotechnology Company Announces Successful Preclinical Study Results For Psoriasis Treatment

Promising In-Vivo Results for Scinai Immunotherapeutics' Psoriatic Human Skin Model.
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biotechnology company known for its focus on developing inflammation and immunology (I&I) biological products, has announced successful in-vivo preclinical study results. The results pertain to its innovative anti IL-17A/F VHH antibody fragment, known as 'NanoAb', which fun...